Growth Hormone
CJC-1295
CJC-1295 (modified GHRH analog)
Long-acting GHRH analog · pairs with ipamorelin for sustained GH release
- FDA Status
- Not FDA-approved · Investigational
- Class
- GHRH analog · with or without DAC (drug affinity complex)
- Sequence
- Modified GHRH 1-29 sequence
- Half-life
- CJC-1295 (no DAC): ~30 min · With DAC: ~6-8 days
Mechanism of action
- GHRH receptor agonism → pituitary GH release
- DAC variant binds albumin → extended half-life
- Increases GH and IGF-1 baseline (vs pulsatile)
- Synergistic with ghrelin agonists (ipamorelin, GHRP-6)
Research areas
- Growth hormone insufficiency
- Anti-aging and body composition research
- Sleep architecture (GH/sleep relationship)
- Wound healing co-administration
Evidence and clinical data
Phase II trials demonstrated 7-10 day sustained GH/IGF-1 elevation with DAC variant. Limited Phase III. Theoretical concern: continuous GHRH signal vs natural pulsatile pattern.
Safety profile
Generally tolerated. Concern around chronically elevated IGF-1 and theoretical cancer risk (no human evidence). DAC variant flagged for sustained signal vs physiological pulsatility.
Why this peptide is trending in 2026: Standard pair with Ipamorelin in GH protocols. Discussion shifts toward "no DAC" forms for more physiological pattern.
Educational use only. PeptideAdvance does not sell CJC-1295, recommend its use, or provide medical advice. The information above is a summary of published research and regulatory status as of April 2026. Some peptides discussed here are not FDA-approved or are restricted under FDA Category 2 — their use outside of authorized clinical research may carry legal and safety implications. Always consult a licensed healthcare professional.